We are excited to have once again assembled many of the leading clinicians and scientists from around the world to drive forward the scientific and medical research agenda in Aspergillus and aspergillosis. There was an overwhelming feeling of success from the first meeting in 2004 in San Francisco where we had 364 attendees from 28 countries exchange ideas and forge new collaborations. The second meeting in 2006 in Athens, Greece had 442 attendees from 44 countries and over 160 abstracts presented.  The Aspergillus field is in a state of rapid advancement, including the publications of the genomes of Aspergillus fumigatus, Aspergillus nidulans and Aspergillus oryzae providing a huge impetus for basic research. Additionally, the launch of several newer antifungals in the last few years and anticipated clinical trials of several more is an important therapeutic step forward, without precedent in mycology. Despite the incidence of invasive aspergillosis increasing and the disease being the leading fungal cause of patient mortality, prior to the 2004 Advances Against Aspergillosis meeting there had been little communication among experts in the area. This is another chance to gather the world's aspergillosis experts in one venue. A fundamental tenet of this research colloquium continues to be to engender collaborative relationships amongst clinicians, scientists, and industry to further advance the field.

Previous Advances Against Aspergillosis Published Proceedings

2004 Conference Proceedings (Med Mycol 2005;43 (suppl 1):1-319)

2006 Conference Proceedings (Med Mycol 2006, In Press)

Clinical Infectious Diseases Supplement (Clin Infect Dis 2003;37 (suppl 3), S155-292)

Accreditation

This activity has been approved for AMA PRA Category 1 Credit™.